|
|
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Number of employees : 107 000 people.
|
|
|
| 2019 | | USD (in Million) | % | | Medical Devices | 12,239 | 38.4% | | Diagnostics | 7,713 | 24.2% | | Nutritionals | 7,409 | 23.2% | | Established Pharmaceuticals | 4,486 | 14.1% | | Other | 57.00 | 0.2% |
|
|
|
| 2018 | 2019 | Delta | | USD (in Million) | % | USD (in Million) | % | | All Other Countries | 11,215 | 36.7% | 11,534 | 36.2% | +2.84% | | United States | 10,839 | 35.4% | 11,398 | 35.7% | +5.16% | | China | 2,311 | 7.6% | 2,346 | 7.4% | +1.51% | | Germany | 1,619 | 5.3% | 1,751 | 5.5% | +8.15% | | Japan | 1,326 | 4.3% | 1,435 | 4.5% | +8.22% | | India | 1,333 | 4.4% | 1,397 | 4.4% | +4.8% | | Switzerland | 1,005 | 3.3% | 1,068 | 3.3% | +6.27% | | The Netherlands | 930.00 | 3% | 975.00 | 3.1% | +4.84% |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
1,979,594,379 |
1,758,150,887 |
88.8% |
209,064,380 |
10.6% |
88.8% |
|
|
|
| Name | Equities | % | | The Vanguard Group, Inc. | 141,677,968 |
8.00% | | Capital Research & Management Co. | 100,782,100 |
5.69% | | Capital Research & Management Co. (Global Investors) | 87,417,734 |
4.94% | | SSgA Funds Management, Inc. | 74,556,021 |
4.21% | | Capital Research & Management Co. (International Investors) | 56,714,070 |
3.20% | | BlackRock Fund Advisors | 42,612,898 |
2.41% | | Wellington Management Co. LLP | 35,926,910 |
2.03% | | Northern Trust Investments, Inc.(Investment Management) | 27,034,512 |
1.53% | | Geode Capital Management LLC | 25,238,694 |
1.43% | | Massachusetts Financial Services Co. | 24,455,855 |
1.38% |
|
|
|
| Name | Equities | % | Valuation |
| Abbott India Limited (500488) | 15,934,048 | 75.0% | 3,563,089,116 USD | | Abbott Laboratories (Pakistan) Limited (ABOT) | 76,259,451 | 77.9% | 352,721,314 USD | | Allergy Therapeutics plc (AGY) | 240,584,571 | 37.6% | 47,820,995 USD | | Domesco Medical Import - Export Joint-Stock Corporation (DMC) | 17,949,800 | 51.7% | 46,457,852 USD | | Kilroy Realty Corporation (KRC) | 165 | 0.0001% | 8,573 USD |
|
| Company contact information |
|
Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064-6400 Phone : +1.224.667.6100 Web : http://www.abbott.com |
|
|
|
JPMorgan appoints General Dynamics CEO as board member |
Sector Medical Equipment, Supplies & Distribution - NEC
Connections : Abbott Laboratories |
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
